Osaic Holdings’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-4,018
Closed -$12.2K 7824
2024
Q4
$12.2K Sell
4,018
-37
-0.9% -$161 ﹤0.01% 5658
2024
Q3
$21K Buy
4,055
+641
+19% +$3.19K ﹤0.01% 5361
2024
Q2
$8.77K Buy
3,414
+679
+25% +$2.32K ﹤0.01% 5857
2024
Q1
$13.5K Sell
2,735
-908
-25% -$5.38K ﹤0.01% 5584
2023
Q4
$32.1K Sell
3,643
-890
-20% -$7.29K ﹤0.01% 5192
2023
Q3
$52K Buy
4,533
+402
+10% +$7.73K ﹤0.01% 4979
2023
Q2
$105K Buy
4,131
+433
+12% +$13.5K ﹤0.01% 4401
2023
Q1
$119K Buy
3,698
+98
+3% +$3.06K ﹤0.01% 4299
2022
Q4
$65.7K Buy
3,600
+276
+8% +$6.31K ﹤0.01% 4739
2022
Q3
$90K Buy
3,324
+486
+17% +$9.86K ﹤0.01% 4470
2022
Q2
$39K Hold
2,838
﹤0.01% 5144
2022
Q1
$56K Buy
2,838
+1,071
+61% +$16.2K ﹤0.01% 5019
2021
Q4
$29K Sell
1,767
-415
-19% -$6.92K ﹤0.01% 5534
2021
Q3
$60K Sell
2,182
-34
-2% -$970 ﹤0.01% 4968
2021
Q2
$65K Buy
2,216
+241
+12% +$6.95K ﹤0.01% 4842
2021
Q1
$55K Sell
1,975
-82
-4% -$2.27K ﹤0.01% 4824
2020
Q4
$58K Sell
2,057
-305
-13% -$7.9K ﹤0.01% 4460
2020
Q3
$59K Buy
2,362
+747
+46% +$19.6K ﹤0.01% 4189
2020
Q2
$39K Sell
1,615
-804
-33% -$15.9K ﹤0.01% 4375
2020
Q1
$37K Buy
+2,419
New +$50K ﹤0.01% 4223

Other funds holding RVNC

Osaic Holdings's RVNC Position: Q1 2025 in Review

Osaic Holdings sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 4,018 shares — an estimated $12.2K sold.

Osaic Holdings first reported a position in RVNC in Q1 2020 and held it in 20 quarters. The position peaked at $119K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Osaic Holdings reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Osaic Holdings sold 4,018 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $12.2K.
  • Osaic Holdings first reported a position in Revance Therapeutics, Inc. in Q1 2020 and held it in 20 quarters.
  • Osaic Holdings's Revance Therapeutics, Inc. position peaked at $119K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Osaic Holdings's 13F filing for Q1 2025, filed 12 May 2025.